Trials / Unknown
UnknownNCT03671265
Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC
A Single Arm Exploratory Study of Chemotherapy Plus Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Locally Advanced Esophageal Squamous Cell Carcinomas
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. This is an openlabel，single center ，non-randomized ，Single Arm Exploratory Study . This clinical study is an investigator-initiated clinical trial（IIT). The objective of this study is to evaluate the efficacy and safety of radiation therapy combined with anti-PD-1 antibody SHR-1210 and chemotherapy in patients with Locally Advanced Esophageal Squamous Cell Carcinomas。
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1210 | SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. |
| RADIATION | IMRT or VMAT | The IMRT or VMAT technique was used in our study. |
| DRUG | Apatinib | Apatinib is a small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2. |
Timeline
- Start date
- 2018-09-17
- Primary completion
- 2019-09-01
- Completion
- 2021-09-01
- First posted
- 2018-09-14
- Last updated
- 2019-01-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03671265. Inclusion in this directory is not an endorsement.